Literature DB >> 18308406

A drug-selected Plasmodium falciparum lacking the need for conventional electron transport.

Martin J Smilkstein1, Isaac Forquer, Atsuko Kanazawa, Jane Xu Kelly, Rolf W Winter, David J Hinrichs, David M Kramer, Michael K Riscoe.   

Abstract

Mitochondrial electron transport is essential for survival in Plasmodium falciparum, making the cytochrome (cyt) bc(1) complex an attractive target for antimalarial drug development. Here we report that P. falciparum cultivated in the presence of a novel cyt bc(1) inhibitor underwent a fundamental transformation in biochemistry to a phenotype lacking a requirement for electron transport through the cyt bc(1) complex. Growth of the drug-selected parasite clone (SB1-A6) is robust in the presence of diverse cyt bc(1) inhibitors, although electron transport is fully inhibited by these same agents. This transformation defies expected molecular-based concepts of drug resistance, has important implications for the study of cyt bc(1) as an antimalarial drug target, and may offer a glimpse into the evolutionary future of Plasmodium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308406      PMCID: PMC2396451          DOI: 10.1016/j.molbiopara.2008.01.002

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  25 in total

1.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

2.  Malaria-parasite mitochondrial dehydrogenases as drug targets: too early to write the obituary.

Authors:  Nicholas Fisher; Patrick G Bray; Stephen A Ward; Giancarlo A Biagini
Journal:  Trends Parasitol       Date:  2007-11-19

3.  Isolation of mitochondria from Plasmodium falciparum showing dihydroorotate dependent respiration.

Authors:  E Takashima; S Takamiya; S Takeo; F Mi-ichi; H Amino; K Kita
Journal:  Parasitol Int       Date:  2001-11       Impact factor: 2.230

4.  Evaluation and lead optimization of anti-malarial acridones.

Authors:  Rolf W Winter; Jane X Kelly; Martin J Smilkstein; Rozalia Dodean; Grover C Bagby; R Keaney Rathbun; Joshua I Levin; David Hinrichs; Michael K Riscoe
Journal:  Exp Parasitol       Date:  2006-07-07       Impact factor: 2.011

5.  Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

Authors:  C J Canfield; M Pudney; W E Gutteridge
Journal:  Exp Parasitol       Date:  1995-05       Impact factor: 2.011

6.  Atovaquone resistance in malaria parasites.

Authors:  Akhil B. Vaidya; Michael W. Mather
Journal:  Drug Resist Updat       Date:  2000-10       Impact factor: 18.500

7.  Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

Authors:  I K Srivastava; H Rottenberg; A B Vaidya
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

8.  Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum.

Authors:  Heather J Painter; Joanne M Morrisey; Michael W Mather; Akhil B Vaidya
Journal:  Nature       Date:  2007-03-01       Impact factor: 49.962

9.  Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.

Authors:  Lise Musset; Bruno Pradines; Daniel Parzy; Rémy Durand; Patricia Bigot; Jacques Le Bras
Journal:  J Antimicrob Chemother       Date:  2005-11-30       Impact factor: 5.790

10.  Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment.

Authors:  Lise Musset; Jacques Le Bras; Jérôme Clain
Journal:  Mol Biol Evol       Date:  2007-05-07       Impact factor: 16.240

View more
  19 in total

1.  Intraerythrocytic stages of Plasmodium falciparum biosynthesize menaquinone.

Authors:  Renata Tonhosolo; Heloisa B Gabriel; Miriam Y Matsumura; Fernanda J Cabral; Márcio M Yamamoto; Fábio L D'Alexandri; Rodrigo A C Sussmann; Rodrigo Belmonte; Valnice J Peres; Dean C Crick; Gerhard Wunderlich; Emília A Kimura; Alejandro M Katzin
Journal:  FEBS Lett       Date:  2010-10-29       Impact factor: 4.124

2.  Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.

Authors:  Allison M Stickles; Martin J Smilkstein; Joanne M Morrisey; Yuexin Li; Isaac P Forquer; Jane X Kelly; Sovitj Pou; Rolf W Winter; Aaron Nilsen; Akhil B Vaidya; Michael K Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.

Authors:  Jennifer L Guler; John White; Margaret A Phillips; Pradipsinh K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

4.  Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance.

Authors:  Louise M Hughes; Charlotte A Lanteri; Michael T O'Neil; Jacob D Johnson; Gordon W Gribble; Bernard L Trumpower
Journal:  Mol Biochem Parasitol       Date:  2011-01-18       Impact factor: 1.759

5.  Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.

Authors:  Allison M Stickles; Mariana Justino de Almeida; Joanne M Morrisey; Kayla A Sheridan; Isaac P Forquer; Aaron Nilsen; Rolf W Winter; Jeremy N Burrows; David A Fidock; Akhil B Vaidya; Michael K Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

6.  Quinolone-3-diarylethers: a new class of antimalarial drug.

Authors:  Aaron Nilsen; Alexis N LaCrue; Karen L White; Isaac P Forquer; Richard M Cross; Jutta Marfurt; Michael W Mather; Michael J Delves; David M Shackleford; Fabian E Saenz; Joanne M Morrisey; Jessica Steuten; Tina Mutka; Yuexin Li; Grennady Wirjanata; Eileen Ryan; Sandra Duffy; Jane Xu Kelly; Boni F Sebayang; Anne-Marie Zeeman; Rintis Noviyanti; Robert E Sinden; Clemens H M Kocken; Ric N Price; Vicky M Avery; Iñigo Angulo-Barturen; María Belén Jiménez-Díaz; Santiago Ferrer; Esperanza Herreros; Laura M Sanz; Francisco-Javier Gamo; Ian Bathurst; Jeremy N Burrows; Peter Siegl; R Kiplin Guy; Rolf W Winter; Akhil B Vaidya; Susan A Charman; Dennis E Kyle; Roman Manetsch; Michael K Riscoe
Journal:  Sci Transl Med       Date:  2013-03-20       Impact factor: 17.956

7.  Proteomic analysis revealed alterations of the Plasmodium falciparum metabolism following salicylhydroxamic acid exposure.

Authors:  Marylin Torrentino-Madamet; Lionel Almeras; Christelle Travaillé; Véronique Sinou; Matthieu Pophillat; Maya Belghazi; Patrick Fourquet; Yves Jammes; Daniel Parzy
Journal:  Res Rep Trop Med       Date:  2011-09-08

8.  Transcript level responses of Plasmodium falciparum to antimycin A.

Authors:  Sarah J Tarr; R Ellen R Nisbet; Christopher J Howe
Journal:  Protist       Date:  2012-04-12

9.  Progress in the Optimization of 4(1H)-Quinolone Derivatives as Antimalarials Targeting the Erythrocytic, the Exoerythrocytic and the Transmitting Stages of the Malaria Parasite.

Authors:  Fabian Brockmeyer; Roman Manetsch
Journal:  Chimia (Aarau)       Date:  2017-04-26       Impact factor: 1.656

10.  Robenidine Analogues Are Potent Antimalarials in Drug-Resistant Plasmodium falciparum.

Authors:  Alina Krollenbrock; Yuexin Li; Jane Xu Kelly; Michael K Riscoe
Journal:  ACS Infect Dis       Date:  2021-03-16       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.